Drugs Information:
Triheptanoin
Basic Information
|
||
ID | DDInter1869 | |
Drug Type | small molecule | |
Molecular Formula | C24H44O6 | |
Molecular Weight | 428.610 | |
CAS Number | 620-67-7 | |
Description | Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation.[L14612] In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly.[A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.[A214817] Triheptanoin was granted FDA approval on 30 June 2020.[L14612] | |
ATC Classification | A16AX17 | |
IUPAC Name | 1,3-bis(heptanoyloxy)propan-2-yl heptanoate | |
InChI | PJHKBYALYHRYSK-UHFFFAOYSA-N | |
Canonical SMILES | CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC | |
Useful Links | DrugBank PubChem Substance ChemSpider Wikipedia ChEMBL ZINC |
Interactions with
Triheptanoin
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|